Incannex Healthcare (ASX: IHL), a pharmaceutical development company, has taken a major step towards the advancement of IHL-42X phase 2b obstructive sleep apnoea (‘OSA’) clinical trial by announcing the recruitment of first patients of the study. The study is aiming to investigate the safety and efficacy of the drug candidate in the treatment of OSA.
药物开发公司Incannex Healthcare（ASX：IHL）通过宣布已成功招募第一批患者，为候选药IHL-42X的2b期阻塞性睡眠呼吸暂停（OSA）临床试验的推进迈出重要一步。该研究旨在研究候选药物IHL-42X在OSA治疗中的安全性和有效性。
Incannex Healthcare (ASX: IHL) has announced excellent results from its preclinical in vivo (animal) study which investigated the neuroprotective effectof IHL-216A in reducing neuronal cell death or disruption after head traumas.
药物开发公司Incannex Healthcare（ASX：IHL）收到来自Creative Biolabs（美国）的IHL-216A临床前动物（体内）试验计划的积极结果，该计划研究在头部创收后，药物在减少颅脑外伤后神经元细胞死亡或破坏方面的神经保护功能。
Clinical Stage pharmaceutical development company Incannex Healthcare Limited (ASX: IHL) has announced a partnership agreement with Monash University to conduct a Phase 2 randomised double-blind active-placebo-controlled trial to assess the safety and efficacy of psilocybin-assisted psychotherapy in the treatment of Generalised Anxiety Disorder (‘GAD’).
临床阶段药物开发公司Incannex Healthcare Limited（ASX：IHL）宣布与莫纳什大学（Monash University）达成合作伙伴关系协议，以进行一项2期随机双盲活性安慰剂对照试验，以评估psilocybin（一种迷幻药）辅助心理疗法在治疗广泛性焦虑症（GAD）中的安全性和有效性。
Incannex Healthcare (ASX: IHL) has resumed its second day elevated trading volume following the announcement of positive IHL-675A in vivo (animal) results on the potency of its anti-inflammatory action.
大麻药物开发商Incannex Healthcare（ASX：IHL）宣布有关其IHL-675A的抗炎效力和协同活性体内结果以及即将与FDA召开Pre-IND会议，股价跳空高开。
Clinical stage drug developer Incannex Healthcare (ASX: IHL) announced that the key components of its cannabinoid drug candidate IHL-675A showed strong synergistic activity to inhibit inflammation in in vitro preclinical studies.
临床阶段药物开发商Incannex Healthcare（ASX：IHL）宣布，其大麻素候选药物IHL-675的关键成分在体外临床前研究中显示出强大的协同活性，可强力抑制炎症。该候选药物可能是败血症相关急性呼吸窘迫综合征（SAARDS）的潜在治疗方法，该病是新冠病毒的死亡主因。